If they qualify for GLP-1s, they should only get the drugs through real pharmacies
Read More The rise of obesity Development, investments, partnerships climb, but safety is key The ability of obesity medications to impact co-morbidities, reducing the symptoms and costs associated with down-the-road disease, has attracted significant attention throughout the biopharma industry
Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, et al
For researchers interested in switching between the two , conversion is not straightforward since they work through different receptor combinations
Some patients use a maintenance plan for a few months, while others may need longer support depending on their goals, response to medication, and overall health
The tradeoff is a new dysesthesia signal (4.4 to 20.9% at 12 mg)